Brief: Decibel Therapeutics Receives Orphan Drug And Rare Pediatric Disease Designations For Db-Oto For The Treatment Of Otoferlin-Related Congenital Hearing Loss
09/09/2021 13:17
Sept 9 (Reuters) - Decibel Therapeutics Inc DBTX.O :
* DECIBEL THERAPEUTICS RECEIVES ORPHAN DRUG AND RARE
PEDIATRIC
DISEASE DESIGNATIONS FOR DB-OTO FOR THE TREATMENT OF
OTOFERLIN-RELATED CONGENITAL HEARING LOSS
* DECIBEL THERAPEUTICS - LOOKING FORWARD TO INITIATING A
PHASE 1/2
CLINICAL TRIAL OF DB-OTO IN PEDIATRIC PATIENTS IN 2022
Source text for Eikon: ID:nGNX9LvywN
Further company coverage: DBTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Decibel Therapeutics
See all newsU.S. STOCKS ON THE MOVE-Domo, BlackBerry, Rite Aid
U.S. STOCKS ON THE MOVE-Decibel Therapeutics, Affirm Holdings, Medtronic
Decibel rises on FDA's 'fast-track' tag for hearing-loss therapy
Brief: Decibel Therapeutics Says US Food And Drug Administration Had Granted Fast Track Designation For DB-OTO
Decibel Therapeutics Inc reports results for the quarter ended in June - Earnings Summary